Evidence map›Paper›PMID 28549390›Full record

ArticlePathogens and global health2017

Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.

Sweta Mishra, Praveen K Bharti, Man M Shukla, Nazia A Ali, Sher S Kashyotia, Avdhesh Kumar, Akshay C Dhariwal, Neeru Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens and global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. An analysis ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Artemisinin Resistance Outside of Southeast Asia.The American journal of tropical medicine and hygiene · 2018
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sweta Mishraa National Institute for Research in Tribal Health , ICMR , Jabalpur , India.
Praveen K Bhartia National Institute for Research in Tribal Health , ICMR , Jabalpur , India.
Man M Shuklaa National Institute for Research in Tribal Health , ICMR , Jabalpur , India.
Nazia A Alia National Institute for Research in Tribal Health , ICMR , Jabalpur , India.
Sher S Kashyotiab National Vector Borne Disease Control Programme , Delhi , India.
Avdhesh Kumarb National Vector Borne Disease Control Programme , Delhi , India.
Akshay C Dhariwalb National Vector Borne Disease Control Programme , Delhi , India.
Neeru Singha National Institute for Research in Tribal Health , ICMR , Jabalpur , India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of P. falciparum resistant strain has led to a significant resurgence of malaria morbidity and mortality. The current cornerstone in malaria treatment in India is Artemisinin based Combination (Artesunate + Sulphadoxine-Pyrimethamine) Therapy (ACT) for treatment of uncomplicated P. falciparum malaria since 2010. In the present study we assessed the therapeutic efficacy of ACT and molecular monitoring of antimalarial resistance. Therapeutic efficacy was determined by in vivo method using 28 days follow-up. Molecular genotyping of dihydrofolate reductase (dhfr), dihydropteroate synthase (dhps) and kelch13 genes were analyzed. msp-1 and msp-2 genotyping were used to differentiate recrudescence. Therapeutic efficacy of ACT was determined in 237 patients over the three year period. Most of the patients showed adequate clinical and parasitological response (99.6%). Molecular study revealed that 72% parasites were of mutant genotype (27.2% single mutants, 43.5% double mutants and 1.3% triple mutants) for pfdhfr while pfdhps showed 78.2% wild type alleles and 21.8% mutants (18.1% single mutants and 3.7% double mutants). Analysis of total 135 samples revealed mutation in k13 gene along with non-synonymous single mutation at codon M579T (1.5%) and double mutations at codon M579T & N657H in 37%. ACT remains effective for the treatment of uncomplicated P. falciparum malaria in Madhya Pradesh, Central India. However, increasing mutation in pfdhfr (particularly triple mutations) and pfdhps may reduce susceptibility to partner drug SP and mutation in k13 propeller gene, highlighting the need for continuous monitoring of the efficacy of ACT.

Indexed as

Drug ResistanceAdolescentAdultAgedAged, 80 and overAntimalarialsArtemisininsArtesunateChildChild, PreschoolDrug CombinationsEpidemiological MonitoringFemaleGenes, ProtozoanGenotypeGenotyping TechniquesAntimalarialsArtemisininsArtesunateDrug Combinationsfanasil, pyrimethamine drug combinationPyrimethamineSulfadoxineACT (Artesunate + Sulphadoxine-Pyrimethamine)Central Indiadrug resistancek13 geneMalariamolecular monitoringPlasmodium falciparumtherapeutic efficacy

Identifiers

PMID28549390
PMCPMC5498763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.